Member Info for Fruitsnveg

I'v ebeen grappling with UK Gov's seeming 'hands off' approach to Synairgen has always been baffling. Could this explain it:
Back at the start of the Pandemic when Synairgen were going through the motions with the US authorities to get selected for ACTIV trial, I suspect the financial burden of the clinical trials were taken on by the USA *on the basis that UK Gov would relinquish first dibs at supply were the drug successful*. The Trump Admin did this with other companies, so why not Synairgen? It explains why UK Gov dare not mention our name, but have, as RM has always said, helped us through various agencies, behind the scenes, to cut through some of the bureaucracy and smooth the path as it were. RM has always praised their 'support'. It would also explain why we abruptly pulled out of the other UK trial in 2020. And it would explain why, at the outset, RM and Co referred to the fact that "whatever happens, Synairgen will always be a British success story".
Thoughts?

Apologies if already posted. Interesting comment by Cuddon regarding Political Clout.

https://www.sharesmagazine.co.uk/news/shares/synairgen-surges-as-us-covid-19-study-advances-to-final-stage-trials

"Shares in respiratory drug development company Synairgen (SNG:AIM) rallied 13% to 166.4p after a US study recommended its inhalation treatment for severe viral lung infections should advance to final stage trials.
Although Synairgen hasn’t received any data from the US-based ACTIV-2 outpatient study of mild to moderate COVID-19 patients, the company was informed that the external data safety monitoring board recommended its SNG001 formulation advance to Phase 3 trails.
Numis healthcare analyst Paul Cuddon said: ‘we would assume a clinical benefit has been observed that warrants continuation into larger pivotal studies.
‘The scientific logic for boosting the body's innate antiviral response in the upper and lower airways remains robust and scientific studies remain highly supportive of this treatment approach.’
Chief executive Richard Marsden said: ‘In addition to the ACTIV-2 trial, our own Phase III SPRINTER study assessing SNG001 in hospitalised COVID-19 patients, is also progressing well and we expect top-line results in early 2022.’

POLITICAL CLOUT
The US trial is sponsored by NIAID (National Institute of Allergy and infectious disease) and run by the AIDS Clinical Trials Group which carries significant political and clinical weight, according to Cuddon.
This will further raise the profile of SNG001 ahead of the key phase three trials, an important aspect in terms of recruiting patients.
The debate around vaccine longevity and lack of enthusiasm for booster programmes demonstrate the need for alternative treatments to combat current and future variants of Covid-19.
Cuddon believes Synairgen’s SNG001 is ‘the most promising treatment option for COVID-19 that addresses the key deficiencies of the current vaccination and treatment strategies'."

lol hold4. Not a lot has changed through the centuries.

Finger in the pulse as always Pmjh. It’s going to be a fun ride from here. Nice to see you back.

OK I take it back. He mentioned it. My bad.

Useless. He never mentioned that you can't get the Booster until at least 6 month shave passed since 2nd vaccine!! Give me strength.

He better mention Synairgen. He just better!

Thanks Matlm, that is precisely what I should have said rather than waffle as I did :-). I understand the mechanism, my question really, as you so eloquently put it, is whether "future variants will or can move away from the mechanism of IFN suppression"? Could that happen? I know it's unlikely, but in terms of risk, could it?

I will read that article, thanks for the link.

Thanks for reposting that Mike109, worth remembering, esp. the bit about efficacy at reducing symptoms.

Question: could we come up against a variant that the drug doesn't work against (if so liklihood low as it's already proven on 1 or 2 so far)?

The message is getting out (in the MSM) and the SP is holding up. I feel the timing is good mid-week - more talk of Synairgen to come in the weekend newspapers?? and coupled with today's grim headlines this couldn't get into the public's consciousness at a better time. I imagine the SP will stay strong at least for the next few days.

That's a great question to put to any journo friends, if you know of any Brand..?
I'd like to understand the logic behind this, we know it's baffling.

Question to the more medically informed / scientific heads amongst us (though feel free to chip in even if you don't categorise yourself thus): how do we see SNG001 faring in P3 given the changes in protocol and different trial design? Yes it's a far way out to the end of P3 and many will have presumably disinvested on the back of Sprinter results by then, but I'm genuinely interested to hear thoughts as to how SNG001 might stack up in that final lengthy trial, given what we know the drug needs to do to succeed in P3. I'm looking at the bigger picture rather than the details here. Be good to know how people view this.

On a separate note, well done everyone who sat tight until today, and congrats to employees of Synairgen who are making it happen.

Congrats you lovely people who kept the faith. SNG001 is another step closer to saving lives.
What a great day!

Kiwi, I think yours is a plausible assumption ref Roche. Now more so than ever one would think.

Andybe4,
Risk is correlated to return. If you want low risk you accept a low return. You buy a goverment bond. If you want a high return you accept the risk, both mitigated and unmitigated, success, failures, delays, warts and all. You seem to believe it's a stock worth owning, but it's not worth the wait. Impatience is a thief.

Andy,
"literally nothing good has happened in a whole year since the fund raise."
It's obvious from your incessant whinging that you did little to no research - the disappointment you now feel (if it's real) is unjustified and unrealistic. You expected to plough money into a company without considering the realties of how a small no-name biotech would navigate the inevitable massive hurdles in a world-first raging pandemic? More fool you. You expected a 10 bagger on what you 'assumed' would be pay day and damn it if this company doesn't deliver when you expect it to? More fool you. Many of us have been under water here for longer than you've been on this BB. We are prepared to wait, not just for an ROI, but for a therapeutic that may one day save our nearest and dearest. That likelihood is now higher than it's ever been. We don't invest on blind faith, we base our decisions on data. And so far I can't see a gaping hole in that data, if you do feel free to speak up now. Most of us know what we bought into and we knew the very real risks involved (including delays of weeks). My advice to you is to wise up, do a bit more research before you throw your money at something, and if it doesn't meet your exacting time standard or you lack the patience to weather the waves, refrain from investing altogether. You'll be eternally disappointed.

When did Polygon start buying Kevin?

I'm thinking of calling it ACDC after the band. Legends.
Anyone with me?

23 million (approx), not 2million. That was a typo. 23 million equates to 1 in 13 Americans, so it's a lot.